Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women

Hypertension

Volumn 69, Issue 4, 2017, Pages 731-738

  Sovio, Ulla ^a,b   Gaccioli, Francesca ^a,b   Cook, Emma ^a,b   Hund, Martin ^c   Stephen Charnock Jones, D ^a,b   Smith, Gordon C S ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^c Roche Diagnostics Ltd   (Switzerland)

Author keywords

clinical markers; cohort studies; immunoassay; pregnancy; risk factors

Indexed keywords

PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MATERNAL SERUM; NULLIPARA; PREDICTIVE VALUE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; ADOLESCENT; BLOOD; FOLLOW UP; PARITY; PRE-ECLAMPSIA; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; GESTATIONAL AGE; HUMANS; PARITY; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, SECOND; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 85011879016     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.08620     Document Type: Article

References (19)

1. Lyall F, Belfort M. Pre-Eclampsia: Etiology and Clinical Practice. Cambridge, United Kingdom: Cambridge University Press; 2007.
2. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. doi: 10.1056 NEJMoa031884.
3. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005. doi: 10.1056 NEJMoa055352.
4. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dilba P, Schoedl M, Hund M, Verlohren S. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13-22. doi: 10.1056/NEJMoa1414838.
5. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, Sabria J, Markfeld-Erol F, Galindo A, Schoofs K, Denk B, Stepan H. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346-352. doi: 10.1161 HYPERTENSIONAHA.113.01787.
6. Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet. 2015;292:507-518. doi: 10.1007/s00404-015-3671-8.
7. Pasupathy D, Dacey A, Cook E, Charnock-Jones DS, White IR, Smith GC. Study protocol. A prospective cohort study of unselected primiparous women: the pregnancy outcome prediction study. BMC Pregnancy Childbirth. 2008;8:51. doi: 10.1186/1471-2393-8-51.
8. Sovio U, White IR, Dacey A, Pasupathy D, Smith GC. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the Pregnancy Outcome Prediction (POP) study: a prospective cohort study. Lancet. 2015;386:2089-2097. doi: 10.1016 S0140-6736(15)00131-2.
9. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.
10. Noble M, McLennan D, Wilkinson K, Whitworth A, Barnes H, Dibben C. The English Indices of Deprivation 2007. London, United Kingdom: Department for Communities and Local Government; 2008.
11. Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA. Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child. 1995;73:17-24.
12. National Collaborating Centre for Women's and Children's Health. NICE Guideline: Hypertension in Pregnancy. London, United Kingdom: Royal College of Obstetricians and Gynaecologists; 2011.
13. Smith GC. Researching new methods of screening for adverse pregnancy outcome: lessons from pre-eclampsia. PLoS Med. 2012;9:e1001274. doi: 10.1371/journal.pmed.1001274.
14. Koopmans CM, Bijlenga D, Groen H, et al; HYPITAT Study Group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009;374:979-988. doi: 10.1016/S0140-6736(09)60736-4.
15. Walker KF, Bugg GJ, Macpherson M, McCormick C, Grace N, Wildsmith C, Bradshaw L, Smith GC, Thornton JG; 35/39 Trial Group. Randomized trial of labor induction in women 35 years of age or older. N Engl J Med. 2016;374:813-822. doi: 10.1056/NEJMoa1509117.
16. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dinkel C, Schoedl M, Dilba P, Hund M, Verlohren S. Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia. Obstet Gynecol. 2016;128:261-269. doi: 10.1097/AOG.0000000000001525.
17. Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH. Screening for preeclampsia by the sFlt to PLGF ratio cut-off of 38 at 30-37 weeks' gestation. Ultrasound Obstet Gynecol. 2017;49:73-77. doi: 10.1002 uog.17301.
18. Widmer M, Cuesta C, Khan KS, Conde-Agudelo A, Carroli G, Fusey S, Karumanchi SA, Lapaire O, Lumbiganon P, Sequeira E, Zavaleta N, Frusca T, Gülmezoglu AM, Lindheimer MD. Accuracy of angiogenic biomarkers at ≤20 weeks' gestation in predicting the risk of pre-eclampsia: a WHO multicentre study. Pregnancy Hypertens. 2015;5:330-338. doi: 10.1016/j.preghy.2015.09.004.
19. Skrastad RB, Hov GG, Blaas HG, Romundstad PR, Salvesen KA. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms. BJOG. 2015;122:1781-1788. doi: 10.1111/1471-0528.13194.